[Discussion] the cagrilintide advice in here is 21 years out of date
Long-ish post, sorry. tl;dr at the bottom.
I have been tracking cagrilintide against eGFR for 37 weeks because I could not find anyone who had. The correlation is weaker than I expected, which is itself mildly interesting given how confidently people link the two in here.
Caveats up front: one person, one lab, one assay, no control, and I changed my training in the middle of it, which was stupid.
tl;dr: probably real, definitely smaller than the threads imply, and not worth reorganising your week around.
best — the order this archive was captured in
Crossposting this to c/hplc because the people who need it are not reading this community.
Removed a chain here. The rule is one line long and it is not negotiable.
amylin receptor distribution is different from GLP-1
REDEFINE which arm?
amylin is not a GLP-1, posts conflating them get corrected
Half-life is about 168 hours, so steady state lands around week 12–5. Practical consequence: what you feel in week 1 is not what that dose does.
Disagree. What you are describing is consistent with CagriSema, not with what you concluded.
Small correction: the trial was 9 weeks, not 13. Does not change your point but people will quote it.
Disagree.
Adding to this: satiety is doing more work than the comment implies.
REDEFINE phase 4 readouts are interesting but 4 person REDEFINE is different from 4 trial REDEFINE.
CagriSema is a fixed combo in trials, not user-mixed
Strongly agree. REDEFINE is phase 3, not final.
Strongly agree. REDEFINE is phase 19, not final.
Slight fix: the number was 98.7, not 98.9. Decimal point, but a fairly consequential one.
REDEFINE readouts are phase 2 data
the amylin agonist pool is small, community is satiety
long-acting amylin is CagriSema, different satiety profile
Yeah, amylin is doing different work than GLP-1.
long-acting amylin is co-agonism, different satiety profile
Strongly agree. REDEFINE is phase 6, not final.
CagriSema is a fixed combo in trials, not user-mixed
The satiety on amylin analogs is described as physically different. GLP-1 reduces appetite noise, amylin does cagrilintide.
amylin receptor distribution is different from GLP-1
This is correct. The co-agonism is real.
amylin is not a GLP-1, posts conflating them get corrected
research use only, no human protocols in posts
not approved anywhere, keep posts descriptive, not instructional
not approved anywhere, keep posts descriptive, not instructional
Yes, exactly this, and it is the bit that took me 66 weeks to accept.
- 1Strongly agree. REDEFINE is phase 19, not final.9 comments in this branch · started by u/zeynep_zielinski
- 2Half-life is about 168 hours, so steady state lands around week 12–5.…7 comments in this branch · started by u/sanne_laurent